ID   INT-MEL-16/2
AC   CVCL_HE37
SY   Me9923/M; Me9923
DR   Cosmic; 2759874
DR   Wikidata; Q54897762
RX   DOI=10.1007/0-306-46872-7_16;
RX   PubMed=9637706;
CC   HLA typing: A*02; B*41,50; C*w02,06 (PubMed=9637706).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Asp79fs*6 (c.235_248del14); Zygosity=Homozygous (PubMed=9637706).
CC   Sequence variation: Mutation; HGNC; HGNC:914; B2M; Simple; p.Tyr86Ter (c.258C>G); Zygosity=Homozygous (PubMed=9637706).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_F250 ! INT-MEL-16/1
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 10
//
RX   DOI=10.1007/0-306-46872-7_16;
RA   Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.;
RT   "Melanoma: the Milan melanoma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=9637706; DOI=10.1172/JCI498; PMCID=PMC508863;
RA   Hicklin D.J., Wang Z.-G., Arienti F., Rivoltini L., Parmiani G.,
RA   Ferrone S.;
RT   "Beta2-microglobulin mutations, HLA class I antigen loss, and tumor
RT   progression in melanoma.";
RL   J. Clin. Invest. 101:2720-2729(1998).
//